# Appendix H. Applicability of Individual Studies

Table 47. Evaluation of applicability for individual randomized controlled trials

| Author,  Year | Effectiveness Study Designation and Composite Score | Effectiveness Study Criteria Met | Applicability Limitation Category | Specific Factors Limiting Applicability |
| --- | --- | --- | --- | --- |
| CT5, 2012 | Study Designation:  Efficacy study  Composite Score:  4of 7 | 1. Assessed final health outcomes 2. Adequate study duration with clinically relevant treatments 3. Assessed adverse outcomes 4. Used intention-to-treat analysis | Population, Outcomes, Setting | * + High male to female ratio (M: 79.5% F: 20.5%)   + More stringent eligibility criteria   + Duration of followup for final health outcomes (Psychological outcomes – 24 weeks)   + Duration of followup for adverse health outcomes (AST, ALT, HTN, Injection site reaction, Infections – NR)   + Conducted in Korea |
| Barker, 2011 | Study Designation:  Effectiveness study  Composite Score:  6 of 7 | 1. Enrolled primary care population 2. Assessed final health outcomes 3. Adequate study duration with clinically relevant treatments 4. Assessed adverse outcomes 5. Adequate sample size 6. Used intention-to-treat analysis | Population, Outcomes, Setting | * + More stringent eligibility criteria   + Duration of followup for final health outcomes (MACE, diabetes – 26 weeks)   + Duration of followup for adverse outcomes (malignancy, infections – 26 weeks)   + Conducted in Europe |
| Caproni, 2009 | Study Designation:  Efficacy study  Composite Score:  3 of 7 | 1. Enrolled primary care population 2. Assessed adverse outcomes 3. Used intention-to-treat analysis | Population, Outcomes, Setting | * + More stringent eligibility criteria   + Did not assess final health outcomes   + Duration of followup for intermediate health outcomes (PASI – 12 weeks)   + Inadequate sample size   + Conducted in Italy |
| Gisondi, 2008a | Study Designation:  Efficacy study  Composite Score:  4 of 7 | 1. Enrolled primary care population 2. Adequate study duration with clinically relevant treatments 3. Assessed adverse outcomes 4. Used intention-to-treat analysis | Population, Outcomes, Setting | * + More stringent eligibility criteria   + Did not assess final health outcomes   + Inadequate sample size   + Conducted in Italy |
| Saurat, 2008 | Study Designation:  Effectiveness study  Composite Score:  6 of 7 | 1. Enrolled primary care population 2. Assessed final health outcomes 3. Adequate study duration with clinically relevant treatments 4. Assessed adverse outcomes 5. Adequate sample size 6. Used intention-to-treat analysis | Population, Outcomes, Setting | * + More stringent eligibility criteria   + Duration of followup for final health outcomes (mortality – 70 days after last treatments)   + Duration of followup for adverse events (infections – 70 days after last followup)   + Conducted in Europe and Canada |